Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: A systematic review

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Zhang, Chenglong ^a   Wen, Ji ^a   Li, Zi ^a   Fan, Junming ^b  

^a SICHUAN UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Chronic kidney disease mineral and bone disorder; Hemodialysis; Lanthanum carbonate; Peritoneal dialysis; Systematic review

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; CALCIUM PHOSPHATE; LANTHANUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ABDOMINAL PAIN; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BRONCHITIS; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPUTER PROGRAM; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPOTENSION; META ANALYSIS; MINERAL BONE DISORDER; MUSCLE CRAMP; MYALGIA; NAUSEA; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRURITUS; REVIEW; RHINITIS; SYSTEMATIC REVIEW; VOMITING;

CHINA; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; LANTHANUM; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84885507751     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-226     Document Type: Review

References (62)

1. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int 2006 69 1945 1953 10.1038/sj.ki.5000414 16641930 (Pubitemid 43924257)
2. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL, Kidney Int 2007 71 1 31 38 10.1038/sj.ki.5002009 17091124 (Pubitemid 44967731)
3. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Block GA, Pork FK, Am J Kidney Dis 2000 35 1226 1237 10.1016/S0272-6386(00)70064-3 10845841 (Pubitemid 30354431)
4. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF, JAMA 2011 305 11 1119 1127 10.1001/jama.2011.308 21406649
5. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC, Am J Kidney Dis 2008 52 531 540 10.1053/j.ajkd.2008.05.020 18657891
6. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK, Am J Kidney Dis 2008 52 519 530 10.1053/j.ajkd.2008.03.020 18514987
7. Medical management of secondary hyperparathyroidism in chronic renal failure. Goodman WG, Nephrol Dial Transplant 2003 18 2 8 10.1093/ndt/gfg1032
8. Clinical and biochemical features of aluminium-related bone disease. Ihle B, Becker G, Kincaid-Smith P, Kidney Int 1986 29 80 S86 10.1038/ki.1986.10
9. How should hyperphosphatemia be managed in dialysis patients? Block G, Uribarri J, Coladonato JA, Fan SL, Cunningham J, Nolan CR, Qunibi WY, Lindberg JS, Semin Dial 2002 15 5 315 328 10.1046/j.1525-139X.2002.00077-1.x 12358631
10. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 342 1478 1483 10.1056/NEJM200005183422003 10816185 (Pubitemid 30318271)
11. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E, Am J Kidney Dis 1999 33 694 701 10.1016/S0272-6386(99)70221-0 10196011 (Pubitemid 29159935)
12. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Slatopolsky EA, Burke SK, Dillon MA, Kidney Int 1999 55 299 307 10.1046/j.1523-1755.1999.00240.x 9893140 (Pubitemid 29004263)
13. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Brezina B, Qunibi WY, Nolan CR, Kidney Int Suppl 2004 9 90 39 S45
14. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J, Clin Nephrol 2004 62 104 115 10.5414/CNP62104 15356967 (Pubitemid 39162762)
15. Lanthanum carbonate. Locatelli F, D'Amico M, Pontoriero G, Drugs 2003 6 688 695
16. Lanthanum carbonate: a new phosphate binder. Behets GJ, Verberckmoes SC, D'Haese PC, de Broe ME, Curr Opin Nephrol Hypertens 2004 13 403 409 10.1097/01.mnh.0000133973.86816.e9 15199290 (Pubitemid 38901619)
17. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Finn WF, Joy MS, Hladik GA, And the Lanthanum Study Group, Clin Nephrol 2004 62 193 201 10.5414/CNP62193 15481851 (Pubitemid 39236623)
18. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Hutchison AJ, Speake M, Al Baaj F, Nephrol Dial Transplant 2004 19 1902 1906 10.1093/ndt/gfh282 15199195 (Pubitemid 38961407)
19. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG, Nephrology (Carlton) 2011 16 290 298 10.1111/j.1440-1797.2010.01412.x 21342323
20. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, de Broe ME, Kidney Int Suppl 2003 6 85 73 S78
21. SPD405-307 Lanthanum Carbonate Study Group: Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC, Clin Nephrol 2008 70 284 295 18826853
22. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D'Haese PC, Nephrol Dial Transplant 2006 21 2217 2224 10.1093/ndt/gfl146 16595583 (Pubitemid 44295048)
23. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Finn WF, SPD 405-307 Lanthanum Study Group, Clin Nephrol 2006 65 191 202 10.5414/CNP65191 16550750 (Pubitemid 43337998)
24. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Wilson R, Zhang P, Smyth M, Pratt R, Current Medical Research & Opinion 2009 25 3021 3028 10.1185/03007990903399398 19845495
25. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF, Am J Kidney Dis 2009 54 619 637 10.1053/j.ajkd.2009.06.004 19692157
26. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Higgins JPT, Green S, The Cochrane Collaboration 2008 Editors Available from http://www.cochrane-handbook.org
27. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Altmann P, Barnett ME, Finn WF, Kidney Int 2007 71 252 259 10.1038/sj.ki.5001932 17035945 (Pubitemid 46160926)
28. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study Group, J Am Soc Nephrol 2008 3 1437 1445 10.2215/CJN.04741107
29. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K, Clin Nephrol 2012 78 216 223 10.5414/CN107257 22874110
30. Long-Term Efficacy and Tolerability of Lanthanum Carbonate: Results from a 3-Year Study. Alastair Hutchison J, Bart M, Johan V, Gernot A, Elfatih M, Roland S, Wolfgang B, Rene J, Andre V, Nephron Clin Pract 2006 102 61 71 10.1159/000088932 (Pubitemid 43087563)
31. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A, Nephron Clin Pract 2005 100 8 19 10.1159/000084653 (Pubitemid 40674602)
32. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R, Clin Nephrol 2009 72 252 258 10.5414/CNP72252 19825330
33. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Kasai S, Sato K, Murata Y, Kinoshita Y, Ther Apher Dial 2012 16 341 349 10.1111/j.1744-9987.2012.01071.x 22817122
34. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Shigematsu T, and the Lanthanum Carbonate Research Group, Ther Apher Dial 2007 12 55 61
35. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Shigematsu T, And the Lanthanum Carbonate Group, Clin Nephrol 2008 70 404 410 10.5414/CNP70404 19000540
36. Control of serum phosphate by oral lanthanum carbonate in patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Al-Baaj F, Speake M, Hutchison AJ, Nephrol Dial Transplant 2005 20 775 782 10.1093/ndt/gfh693 15703206 (Pubitemid 40520656)
37. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Joy MS, Finn WF, Am J Kidney Dis 2003 42 96 107 10.1016/S0272-6386(03)00554-7 12830461 (Pubitemid 36807658)
38. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Chiang SS, Chen JB, Yang WC, Clin Nephrol 2005 63 461 470 10.5414/CNP63461 15960148
39. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Lee YK, Choi HY, Shin SK, Lee HY, Clin Nephrol 2013 79 2 136 142 10.5414/CN107362 23211335
40. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. Jing X, Yi-Xiang Z, Xue-Qing Y, Zhi-Hong L, Li-Ning W, Jiang-Hua C, Ya-Ping F, Zhao-Hui N, Mei W, Fa-Huan Y, Guo-Hua D, Xiang-Mei C, Ai-Ping Z, Chang-Lin M, BMC Nephrol 2013 14 29 10.1186/1471-2369-14-29 23379590
41. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Suki W, Zabaneh R, Cngiano J, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK, Kidney Int 2007 72 9 1130 1137 10.1038/sj.ki.5002466 17728707 (Pubitemid 47609037)
42. Vascular calcification in the uremic patient: a cardiovascular risk? Salgueira M, del Toro N, Moreno-Alba R, Jiménez E, Aresté N, Palma A, Kidney Int Suppl 2003 6 86 119 S121
43. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado Dos Reis L, Edelman A, Lacour B, Jorgetti V, Drüeke TB, Massy ZA, Nephrol Dial Transplant 2012 27 2 505 513 10.1093/ndt/gfr254 21705467
44. Lanthanum carbonate and sevelamer hydrochloride prevent vascular calcification in uremic rats. Rodriguez M, Guerrero F, Lopez I, Aguilera-Tejero E, Rodriguez M, J Am Soc Nephrol 2008 19 164A 10.1681/ASN.2007020156
45. Bile acid binding to sevelamer HCl. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR, Kidney Int 2002 62 2 611 619 10.1046/j.1523-1755.2002.00459.x 12110025 (Pubitemid 34779775)
46. Endotoxin-binding affinity of sevelamer hydrochloride. Perianayagam MC, Jaber BL, Am J Nephrol 2008 28 5 802 807 10.1159/000135691 18506105
47. Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Hauser AB, Azevedo IR, Gonçalves S, Stinghen A, Aita C, Pecoits-Filho R, Blood Purif 2010 30 3 153 158 10.1159/000319850 20861617
48. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Stinghen AE, Gonçalves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, Pecoits-Filho R, Blood Purif 2010 29 4 352 356 10.1159/000302723 20357435
49. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Navarro-González JF, Mora-Fernández C, Muros De Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J, Clin J Am Soc Nephrol 2011 6 9 2272 2279 10.2215/CJN.01650211 21784820
50. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. Chennasamudram SP, Noor T, Vasylyeva TL, J Ren Care 2013 39 2 82 89 10.1111/j.1755-6686.2013.12009.x 23574727
51. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE, Clin J Am Soc Nephrol 2012 7 6 934 942 10.2215/CJN.12891211 22461535
52. D14 C(-260) T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. Koenig W, Khuseyinova N, Hoffmann MM, März W, Fröhlich M, Hoffmeister A, Brenner H, Rothenbacher D, J Am Coll Cardiol 2002 40 1 34 42 10.1016/S0735-1097(02)01937-X 12103253 (Pubitemid 34701374)
53. A randomized, doubleblind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ, Clin Nephrol 2007 68 386 391 10.5414/CNP68386 18184521 (Pubitemid 350258767)
54. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group, Nephron Clin Pract 2008 110 1 15 c23 10.1159/000149239 18667837
55. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Slatopolsky E, Liapis H, Finch J, Kidney Int 2005 68 6 2809 2813 10.1111/j.1523-1755.2005.00753.x 16316357 (Pubitemid 43251027)
56. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Lacour B, Lucas A, Auchere D, Ruellan N, Serre Patey NM, Drueke TB, Kidney Int 2005 67 3 1062 1069 10.1111/j.1523-1755.2005.00171.x 15698446 (Pubitemid 41623331)
57. Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. Yang Z, Schryvers D, Roels F, D'Haese PC, De Broe ME, J Microsc 2006 223 Pt 2 133 139 16911073 (Pubitemid 44222099)
58. Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report. Namagondlu G, Main N, Yates L, Mooney J, Sathyamurthy S, Daryanani I, Crowe A, Ledson T, Banerjee A, J Med Case Rep 2009 9 3 9321
59. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M, Kidney Int 2004 66 3 1239 1247 10.1111/j.1523-1755.2004.00877.x 15327423 (Pubitemid 39121034)
60. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM, Adv Ren Replace Ther 2003 10 2 133 145 10.1053/jarr.2003.50016 12879374 (Pubitemid 36903845)
61. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V, Value Health 2007 10 1 32 41 10.1111/j.1524-4733. 2006.00142.x 17261114 (Pubitemid 46161093)
62. Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J, Ann Nutr Metab 2011 58 4 315 319 10.1159/000331988 21986491